Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Feb 8, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating the use of a medication called oral iohexol for treating a condition known as chylous ascites, which can occur after certain surgeries for abdominal or pelvic cancers. Chylous ascites is characterized by the buildup of a milky fluid in the abdomen, typically after procedures that involve removing lymph nodes. The main goals of the study are to see if oral iohexol can effectively help manage this condition and if it is safe for patients.

To participate in this trial, individuals need to be between 18 and 75 years old and have recently undergone a specific type of surgery called retroperitoneal or extended lymphadenectomy for cancer. They must also have been diagnosed with chylous ascites, which is identified by certain fluid characteristics. However, people with serious heart, liver, or kidney problems, or those who are allergic to iohexol, will not be eligible. Participants can expect to receive treatment with oral iohexol and will be monitored closely for its effects. This trial aims to provide new insights into managing chylous ascites effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients between the ages of 18 and 75 years;
• • Patients underwent retroperitoneal or extended lymphadenectomy for abdominal or pelvic malignant tumors;
• • Patients diagnosisted with postoperative Chylous ascites. Chylous ascites were defined by the presence of non-infectious, milky, or creamy effluent in drainage tubes surpassing 200 mL daily, paired with triglyceride concentrations exceeding 110 mg/dL
• Exclusion Criteria:
• • Patients with severe cardiac, hepatic and renal insufficiency;
• • Patients with a history of iohexol allergy or allergy to contrast media;
• • Patients who have received other interventions;
• • Patients with severe intestinal obstruction or intestinal perforation;
• • Patients who are unable to comply with the requirements of the study or are unable to complete follow-up.